Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
0.6321
-0.0427 (-6.33%)
Aug 14, 2025, 11:45 AM - Market open

Moleculin Biotech Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-26.55-21.76-29.77-29.03-15.89-17.36
Upgrade
Depreciation & Amortization
0.120.130.130.130.160.2
Upgrade
Loss (Gain) From Sale of Assets
-----0.01
Upgrade
Stock-Based Compensation
1.681.731.982.282.371.68
Upgrade
Other Operating Activities
1.46-4.182.45-1.24-6.63-2.26
Upgrade
Change in Accounts Payable
0.72-0.470.40.730.24-1.02
Upgrade
Change in Other Net Operating Assets
1.220.71.22-0.510.80.98
Upgrade
Operating Cash Flow
-21.34-23.86-23.59-27.64-18.95-17.77
Upgrade
Capital Expenditures
--0.01-0.12-0.07-0.02-0.38
Upgrade
Sale of Property, Plant & Equipment
-----0
Upgrade
Investing Cash Flow
--0.01-0.12-0.07-0.02-0.37
Upgrade
Issuance of Common Stock
18.084.664.17-74.7522.57
Upgrade
Repurchase of Common Stock
-0-0.03-0.03-0.02-0.02-0.02
Upgrade
Financing Cash Flow
18.084.644.14-0.0274.7222.55
Upgrade
Foreign Exchange Rate Adjustments
-0.03-0.03-0.02-0.03-0.020.03
Upgrade
Net Cash Flow
-3.29-19.27-19.6-27.7655.734.44
Upgrade
Free Cash Flow
-21.34-23.88-23.72-27.71-18.97-18.15
Upgrade
Free Cash Flow Per Share
-2.54-6.93-12.00-14.53-10.59-27.65
Upgrade
Cash Income Tax Paid
-----0.02
Upgrade
Levered Free Cash Flow
-10.29-14.36-14.6-16.09-10.17-10.77
Upgrade
Unlevered Free Cash Flow
-10.29-14.36-14.6-16.09-10.17-10.77
Upgrade
Change in Working Capital
1.950.231.620.221.04-0.04
Upgrade
Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q